[1]
Wang T, Costa V, Jenkins SG, Hartman BJ, Westblade LF. Acinetobacter radioresistens infection with bacteremia and pneumonia. IDCases. 2019:15():e00495. doi: 10.1016/j.idcr.2019.e00495. Epub 2019 Jan 28
[PubMed PMID: 30906692]
Level 3 (low-level) evidence
[2]
Antunes LC, Visca P, Towner KJ. Acinetobacter baumannii: evolution of a global pathogen. Pathogens and disease. 2014 Aug:71(3):292-301. doi: 10.1111/2049-632X.12125. Epub 2014 Jan 27
[PubMed PMID: 24376225]
[3]
Eze EC, Chenia HY, El Zowalaty ME. Acinetobacter baumannii biofilms: effects of physicochemical factors, virulence, antibiotic resistance determinants, gene regulation, and future antimicrobial treatments. Infection and drug resistance. 2018:11():2277-2299. doi: 10.2147/IDR.S169894. Epub 2018 Nov 15
[PubMed PMID: 30532562]
[4]
Munier AL, Biard L, Legrand M, Rousseau C, Lafaurie M, Donay JL, Flicoteaux R, Mebazaa A, Mimoun M, Molina JM. Incidence, risk factors and outcome of multi-drug resistant Acinetobacter baumannii nosocomial infections during an outbreak in a burn unit. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2019 Feb:79():179-184. doi: 10.1016/j.ijid.2018.11.371. Epub 2018 Dec 6
[PubMed PMID: 30529108]
[5]
Maragakis LL, Perl TM. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2008 Apr 15:46(8):1254-63. doi: 10.1086/529198. Epub
[PubMed PMID: 18444865]
[6]
Playford EG, Craig JC, Iredell JR. Carbapenem-resistant Acinetobacter baumannii in intensive care unit patients: risk factors for acquisition, infection and their consequences. The Journal of hospital infection. 2007 Mar:65(3):204-11
[PubMed PMID: 17254667]
[7]
Zhou HY, Yuan Z, Du YP. Prior use of four invasive procedures increases the risk of Acinetobacter baumannii nosocomial bacteremia among patients in intensive care units: a systematic review and meta-analysis. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2014 May:22():25-30. doi: 10.1016/j.ijid.2014.01.018. Epub 2014 Mar 4
[PubMed PMID: 24607429]
Level 1 (high-level) evidence
[8]
Garnacho-Montero J, Timsit JF. Managing Acinetobacter baumannii infections. Current opinion in infectious diseases. 2019 Feb:32(1):69-76. doi: 10.1097/QCO.0000000000000518. Epub
[PubMed PMID: 30520737]
Level 3 (low-level) evidence
[9]
Giacobbe DR, Mikulska M, Viscoli C. Recent advances in the pharmacological management of infections due to multidrug-resistant Gram-negative bacteria. Expert review of clinical pharmacology. 2018 Dec:11(12):1219-1236. doi: 10.1080/17512433.2018.1549487. Epub 2018 Dec 6
[PubMed PMID: 30444147]
Level 3 (low-level) evidence
[10]
Wong D, Nielsen TB, Bonomo RA, Pantapalangkoor P, Luna B, Spellberg B. Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges. Clinical microbiology reviews. 2017 Jan:30(1):409-447
[PubMed PMID: 27974412]
Level 3 (low-level) evidence
[11]
de Azevedo FKSF, Dutra V, Nakazato L, Mello CM, Pepato MA, de Sousa ATHI, Takahara DT, Hahn RC, Souto FJD. Molecular epidemiology of multidrug-resistant Acinetobacter baumannii infection in two hospitals in Central Brazil: the role of ST730 and ST162 in clinical outcomes. Journal of medical microbiology. 2019 Jan:68(1):31-40. doi: 10.1099/jmm.0.000853. Epub 2018 Dec 5
[PubMed PMID: 30516469]
Level 2 (mid-level) evidence
[12]
Lee CR, Lee JH, Park M, Park KS, Bae IK, Kim YB, Cha CJ, Jeong BC, Lee SH. Biology of Acinetobacter baumannii: Pathogenesis, Antibiotic Resistance Mechanisms, and Prospective Treatment Options. Frontiers in cellular and infection microbiology. 2017:7():55. doi: 10.3389/fcimb.2017.00055. Epub 2017 Mar 13
[PubMed PMID: 28348979]
Level 1 (high-level) evidence
[13]
Harding CM, Hennon SW, Feldman MF. Uncovering the mechanisms of Acinetobacter baumannii virulence. Nature reviews. Microbiology. 2018 Feb:16(2):91-102. doi: 10.1038/nrmicro.2017.148. Epub 2017 Dec 18
[PubMed PMID: 29249812]
[14]
Lees-Miller RG, Iwashkiw JA, Scott NE, Seper A, Vinogradov E, Schild S, Feldman MF. A common pathway for O-linked protein-glycosylation and synthesis of capsule in Acinetobacter baumannii. Molecular microbiology. 2013 Sep:89(5):816-30. doi: 10.1111/mmi.12300. Epub 2013 Jul 12
[PubMed PMID: 23782391]
[15]
Weber BS, Harding CM, Feldman MF. Pathogenic Acinetobacter: from the Cell Surface to Infinity and Beyond. Journal of bacteriology. 2015 Dec 28:198(6):880-7. doi: 10.1128/JB.00906-15. Epub 2015 Dec 28
[PubMed PMID: 26712938]
[16]
Lal B, Vijayakumar S, Anandan S, Veeraraghavan B. Specimen Collection, Processing, Culture, and Biochemical Identification of Acinetobacter spp. Methods in molecular biology (Clifton, N.J.). 2019:1946():1-15. doi: 10.1007/978-1-4939-9118-1_1. Epub
[PubMed PMID: 30798539]
[17]
Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, Kallen A, Limbago B, Fridkin S, National Healthcare Safety Network (NHSN) Team and Participating NHSN Facilities. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infection control and hospital epidemiology. 2013 Jan:34(1):1-14. doi: 10.1086/668770. Epub 2012 Nov 27
[PubMed PMID: 23221186]
[18]
Bozorgmehr R, Bahrani V, Fatemi A. Ventilator-Associated Pneumonia and Its Responsible Germs; an Epidemiological Study. Emergency (Tehran, Iran). 2017:5(1):e26
[PubMed PMID: 28286833]
[19]
Burnham JP, Rojek RP, Kollef MH. Catheter removal and outcomes of multidrug-resistant central-line-associated bloodstream infection. Medicine. 2018 Oct:97(42):e12782. doi: 10.1097/MD.0000000000012782. Epub
[PubMed PMID: 30334966]